Antimicrobial drugs for treating cholera

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Leibovici Weissman, Ya'ara ^a   Neuberger, Ami ^b   Bitterman, Roni ^b   Sinclair, David ^c   Salam, Mohammed Abdus ^d   Paul, Mical ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FURAZOLIDONE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIOLOGY; CHOLERA; CLINICAL FEATURE; DEATH; DEHYDRATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; FECES; HUMAN; LONG TERM CARE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; FLUID THERAPY; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHOLERA; DIARRHEA; FLUID THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943346619     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008625.pub2     Document Type: Review

References (105)

1. Alam A N, Alam N H, Ahmed T, Sack D A. Randomised double blind trial of single dose doxycycline for treating cholera in adults. British Medical Journal 1990;300(6740):1619-21.
2. Bhattacharya S K, Bhattacharya M K, Dutta P, Dutta D, De S P, Sikdar S N, et al.Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrobial Agents and Chemotherapy 1990;34(5):939-40.
3. Bhattacharya M K, Dutta D, Ramamurthy T, Sarkar D, Singharoy A, Bhattacharya S K. Azithromycin in the treatment of cholera in children. Acta Paediatrica 2003;92(6):676-8.
4. Burans J P, Podgore J, Mansour M M, Farah A H, Abbas S, Abu-Elyazeed R, et al.Comparative trial of erythromycin and sulphatrimethoprim in the treatment of tetracycline-resistant Vibrio cholerae O1. Transactions of the Royal Society of Tropical Medicine & Hygiene 1989;83(6):836-8.
5. Butler T, Lolekha S, Rasidi C, Kadio A, del Rosal P L, Iskandar H, et al.Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. American Journal of Medicine 1993;94(3A):187S-94S.
6. Carpenter C C, Sack R B, Mondal A, Mitra P P. Tetracycline Therapy in Cholera. Journal of the Indian Medical Association 1964;43:309-12.
7. Chaudhuri R N, Neogy K N, Sanyal S N, Gupta R K, Manji P. Furazolidone in the treatment of cholera. Lancet 1968;1(7538):332-3.
8. De S, Chaudhuri A, Dutta P, Dutta D, De S P, Pal S C. Doxycycline in the treatment of cholera. Bulletin of the World Health Organization 1976;54(2):177-9.
9. Dutta D, Bhattacharya S K, Bhattacharya M K, Deb A, Deb M, Manna B, et al.Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. Journal of Antimicrobial Chemotherapy 1996;37(3):575-81.
10. Francis T I, Lewis E A, Oyediran A B, Okubadejo O A, Montefiore D, Onyewotu II, et al.Effect of chemotherapy on the duration of diarrhoea, and on vibrio excretion by cholera patients. The Journal of tropical medicine and hygiene 1971;74(8):172-6.
11. Gharagozloo R A, Naficy K, Mouin M, Nassirzadeh M H, Yalda R. Comparative trial of tetracycline, chloramphenicol, and trimethoprim-sulphamethoxazole in eradication of Vibrio cholerae El Tor. British Medical Journal 1970;4(5730):281-2.
12. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clinical Infectious Diseases 1995;20(6):1485-90.
13. Gotuzzo E, Seas C, Echevarria J, Ruiz R, Carrillo C. Oral ciprofloxacin in the treatment of cholera. Drugs 1995;49 Suppl 2:451-3.
14. Grados P, Bravo N, Battilana C. Comparative effectiveness of co-trimoxazole and tetracycline in the treatment of Cholera. Bulletin of the Pan American Health Organization 1996;30(1):36-42.
15. Hossain M S, Salam M A, Rabbani G H, Kabir I, Biswas R, Mahalanabis D. Tetracycline in the treatment of severe cholera due to Vibrio cholerae O139 Bengal. Journal of Health, Population and Nutrition 2002;20(1):18-25.
16. Islam M R. Single dose tetracycline in cholera. Gut 1987;28(8):1029-32.
17. Kabir I, Khan W A, Haider R, Mitra A K, Alam A N. Erythromycin and trimethoprim-sulphamethoxazole in the treatment of cholera in children. Journal of Diarrhoeal Diseases Research 1996;14(4):243-7.
18. Karchmer A W, Curlin G T, Huq M I, Hirschhorn N. Furazolidone in paediatric cholera. Bulletin of the World Health Organization 1970;43(3):373-8.
19. Kaushik J S, Gupta P, Faridi M M, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatrics 2010;47(4):309-15.
20. Khan W A, Dhar U, Begum M, Salam M A, Bardhan P K, Mahalanabis D. Antimicrobial treatment of adults with cholera due to Vibrio cholerae 0139 (synonym Bengal). Drugs 1995;49 Suppl 2:460-2.
21. Khan W A, Begum M, Salam M A, Bardhan P K, Islam M R, Mahalanabis D. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Transactions of the Royal Society of Tropical Medicine & Hygiene 1995;89(1):103-6.
22. Salam M A, Khan W A, Begum M, Bardhan P K, Islam M R, Mahalanabis D. Antimicrobial treatment of cholera. Drugs 1995;49 Suppl 2:466-9.
23. Khan W A, Bennish M L, Seas C, Khan E H, Ronan A, Dhar U, et al.Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996;348(9023):296-300.
24. Khan W A, Saha D, Rahman A, Salam M A, Bogaerts J, Bennish M L. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002;360(9347):1722-7.
25. Lapeysonnie L, Aye H, Rive J, Duchassin M, Blanc M. Controlled trials on place of sulformethoxine on the carrying of choleric vibrions. La Presse Médicale 1971;79(14):637-8.
26. Lindenbaum J, Greenough W B, Islam M R. Antibiotic therapy of cholera. Bulletin of the World Health Organization 1967;36(6):871-83.
27. Lindenbaum J, Greenough W B, Islam M R. Antibiotic therapy of cholera in children. Bulletin of the World Health Organization 1967;37(4):529-38.
28. Lolekha S, Patanachareon S, Thanangkul B, Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scandinavian Journal of Infectious Diseases. Supplementum. 1988;56:35-45.
29. Mihindukulasuriya J C, Velauthapillai N, Lionel N D. A comparative trial of sulphadoxine and tetracycline in the treatment of cholera. Ceylon Medical Journal 1976;21(3):201-3.
30. Moolasart P, Eampokalap B, Supaswadikul S. Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea. The Southeast Asian Journal of Tropical Medicine and Public Health 1998;29(1):108-11.
31. Pierce N F, Banwell J G, Mitra R C, Caranasos G J, Keimowitz R I, Thomas J, et al.Controlled comparison of tetracycline and furazolidone in cholera. British Medical Journal 1968;3(5613):277-80.
32. Rabbani G H, Islam M R, Butler T, Shahrier M, Alam K. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial. Antimicrobial Agents and Chemotherapy 1989;33(9):1447-50.
33. Rabbani G H, Butler T, Shahrier M, Mazumdar R, Islam M R. Efficacy of a single dose of furazolidone for treatment of cholera in children. Antimicrobial Agents and Chemotherapy 1991;35(9):1864-7.
34. Rahaman M M, Majid M A, Alam Akmj, Islam M R. Effects of doxycycline in actively purging cholera patients: a double-blind clinical trial. Antimicrobial Agents and Chemotherapy 1976;10(4):610-2.
35. Roy S K, Islam A, Ali R, Islam K E, Khan R A, Ara S H, et al.A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children. Transactions of the Royal Society of Tropical Medicine & Hygiene 1998;92(4):460-2.
36. Sack D A, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. Antimicrobial Agents and Chemotherapy 1978;14(3):462-4.
37. Saha D, Khan W A, Karim M M, Chowdhury H R, Salam M A, Bennish M L. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005;366(9491):1085-93.
38. Gibson N E. A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh. Evidence-Based Medicine 2006;11(6):181.
39. Saha D, Karim M M, Khan W A, Ahmed S, Salam M A, Bennish M L. Single-dose azithromycin for the treatment of cholera in adults. New England Journal of Medicine 2006;354(23):2452-62.
40. Usubutun S, Agalar C, Diri C, Turkyilmaz R. Single dose ciprofloxacin in cholera. European Journal of Emergency Medicine 1997;4(3):145-9.
41. Wallace C K, Anderson P N, Brown T C, Khanra S R, Lewis G W, Pierce N F, et al.Optimal antibiotic therapy in cholera. Bulletin of the World Health Organization 1968;39(2):239-45.
42. Wallace C K, Anderson P N, Brown T C, Khanra S R, Lewis G W, Pierce N F, et al.Optimal antibiotic therapy in cholera. Bulletin of the World Health Organization 1968;39(2):239-45.
43. Cash R A, Northrup R S, Mizanur Rahman A S. Trimethoprim and sulfamethoxazole in clinical cholera: comparison with tetracycline. Journal of Infectious Diseases 1973;128:Suppl:749-53.
44. Chatterjee H N. Therapy of diarrhoea in cholera. Lancet 1953;265(6794):1045-6.
45. Gotuzzo E. Tratamiento del colera grave: eficacia de lomefloxacino una vez al dia durante tres dias. Revista Espanola de Quimioterapia 1994;7:292-5.
46. Greenough W B 3rd, Gordon R S Jr, Rosenberg I S, Davies B I, Benenson A S. Tetracycline in the Treatment of Cholera. Lancet 1964;1(7329):355-7.
47. Kobari K, Uylangco C, Vasco J. Evaluation of various antimicrobial drugs for the treatment of cholera. Bulletin of the World Health Organization 1967;37(5):810-1.
48. Kobari K, Uylangco C, Vasco J, Takahira Y, Shimizu N. Observations on cholera treated orally and intravenously with antibiotics. With particular reference to the number of vibrios excreted in the stool. Bulletin of the World Health Organization 1967;37(5):751-62.
49. Lahiri S C. Chemotherapy in cholera. British Medical Journal 1951;1(4705):500-4.
50. Mazumdar D N, De S, De S P, Sircar B K. Minocycline, tetracycline and furazolidone in the treatment of cholera. Indian Journal of Medical Research 1977;66(6):917-21.
51. Mazumder D N, Sirkar B K, De S P. Minocycline in the treatment of cholera. A comparison with tetracycline. Indian Journal of Medical Research 1974;62(5):712-8.
52. Okuda J, Ramamurthy T, Yamasaki S. Antibacterial activity of ciprofloxacin against clinical strains of Vibrio cholerae O139 recently isolated from India. Yakugaku Zasshi 2007;127(5):903-4.
53. Pastore G, Rizzo G, Fera G, Schiraldi O. Trimethoprim-sulphamethoxazole in the treatment of cholera. Comparison with tetracycline and chloramphenicol. Chemotherapy 1977;23(2):121-8.
54. Rabbani G H. Cholera. Clinics in gastroenterology. 1986;15(3):507-28.
55. Rabbani G H. Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Danish Medical Bulletin 1996;43(2):173-85.
56. Sagara H, Tomizawa I, Takizawa Y, Nitta Y, Tsunoda T, Yamaguchi T, et al.Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis. The Journal of the Japanese Association for Infectious Diseases 1994; Vol. 68, issue 11:1390-408. [: CN-00109461]
57. Seal S C, Ghosh M M, Ghosal S C. Further trial of aureomycin in the treatment of cholera. British Medical Journal 1954;1(4864):740-2.
58. Seijo A C, Fernandez M, Campos C, Cernigoi B E, Nogueras M, San Juan J, et al.Norfloxacin monodose use in patients with cholera in Salta Argentina. Journal of the São Paulo Institute of Tropical Medicine 1996;38(3):217-9.
59. Uylangco C V, Fabie A E, Mier S G, Santiago L. Oral streptomycin in the treatment of cholera. Journal of the Philippine Medical Association 1965;41(11):763-9.
60. Uylangco C V, Vasco J A, Calilong V P, Villaroman M P. Tetracycline hydrochloride in the treatment of cholera El Tor. Journal of the Philippine Medical Association 1966;42(9):529-38.
61. Uylangco C, Vasco J, Calilong V. Observations on 285 cases on cholera El Tor treated with various antibiotics. Bulletin of the World Health Organization 1967;37(5):812-4.
62. Uylangco C V, Soriano V B. Minocycline and co-trimoxazole in the treatment of cholera El Tor. Modern Medicine of Asia 1978;14(3):8-10.
63. Uylangco C, Santiago L, Pescante M, Menday P, Christensen O. Pivmecillinam, co-trimoxazole and oral mecillinam in gastroenteritis due to Vibrio spp. Journal of Antimicrobial Chemotherapy 1984;13(2):171-5.
64. Wallace C K, Gangarosa E J. Antibiotic drugs in cholera. Annals of Internal Medicine 1968;69(1):166-7.
65. Woodward W E, Rahman A S. Trial of clioquinol in cholera. Lancet 1969;2(7614):270.
66. Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy of Multiple-Dose Ciprofloxacin With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Strains of V. Cholerae O1 or O13. Ongoing study July 2007.
67. Randomized, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of Ciprofloxacin Oral Suspension 20 Mg/Kg With a 3-Day Course of Erythromycin Oral Suspension Administered in a Dose of 12.5 Mg/Kg Every 6 Hours (12 Doses) in the Treatment of Children, With Clinically Severe Cholera Due to V. cholerae O1 or O139. Ongoing study May 2001.
68. Randomized, Double-Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to V. cholerae O1 or O139. Ongoing study December 2002.
69. Alam M, Sultana M, Nair GB, Siddique AK, Hasan NA, Sack RB, et al.Viable but nonculturable Vibrio cholerae O1 in biofilms in the aquatic environment and their role in cholera transmission. Proceedings of the National Academy of Sciences USA 2007;104(45):17801-6.
70. Andrews J R, Basu S. Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet 2011;377(9773):1248-55.
71. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, et al.Cholera surveillance during the Haiti epidemic--the first 2 years. New England Journal of Medicine 2013;368(7):599-609.
72. Bucher H C, Guyatt G H, Griffith L E, Walter S D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
73. Ceccarelli D, Spagnoletti M, Cappuccinelli P, Burrus V, Colombo MM. Origin of Vibrio cholerae in Haiti. Lancet Infectious Diseases 2011;11(4):262.
74. Chambers K. Zimbabwe's battle against cholera. Lancet 2009 Mar 21;373(9668):993-4.
75. De S N. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 1959;183(4674):1533-4.
76. Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One 2010;5(11):e11054.
77. Dutta N K, Panse M V, Kulkarni D R. Role of cholera a toxin in experimental cholera. Journal of Bacteriology 1959;78:594-5.
78. Faruque AS, Alam K, Malek MA, Khan MG, Ahmed S, Saha D, et al.Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. Journal of Health, Population and Nutrition 2007;25(2):241-3.
79. Frerichs RR, Keim PS, Barrais R, Piarroux R. Nepalese origin of cholera epidemic in Haiti. Clinical Microbiology and Infection 2012;18(6):E158-63.
80. Friedrich J O, Adhikari N K, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. Journal of Clinical Epidemiology 2011;64(5):556-64.
81. Friedrich JO, Adhikari NK, Beyene J. Ratio of geometric means to analyze continuous outcomes in meta-analysis: comparison to mean differences and ratio of arithmetic means using empiric data and simulation. Statistics in Medicine 2012;31(17):1857-86.
82. Glass R I, Becker S, Huq M I, Stoll B J, Khan M U, Merson M H, et al.Endemic cholera in rural Bangladesh, 1966-1980. American Journal of Epidemiology 1982;116(6):959-70.
83. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
84. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet 2012;379(9835):2466-76.
85. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration 2008.
86. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5(1):13.
87. ICDDR, b. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Lancet 1993;342(8868):387-90.
88. Ioannidis J P. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. Canadian Medical Association Journal 2009;181(8):488-93.
89. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
90. Mhalu FS, Mmari PW, Ijumba J. Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. Lancet 1979;1(8112):345-7.
91. Ministry of Public Health and Population, Haiti. Pan American Health Organization. CDC. Update: cholera outbreak --- Haiti, 2010. Morbidity and Mortality Weekly Report 2010;59(50):1637-41.
92. Mintz ED, Guerrant RL. A lion in our village--the unconscionable tragedy of cholera in Africa. New England Journal of Medicine 2009;360(11):1060-3.
93. Moore SM, Shannon KL, Zelaya CE, Azman AS, Lessler J. Epidemic Risk from Cholera Introductions into Mexico. PLoS Currents: Outbreaks 2014;6:ecurrents.outbreaks.c04478c7fbd9854ef6ba923cc81eb799. [DOI: 10.1371/currents.outbreaks.c04478c7fbd9854ef6ba923cc81eb799]
94. Copenhagen: The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.0. The Cochrane Collaboration, 2008.
95. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004;363(9404):223-33.
96. Seas C, DuPont HL, Valdez LM, Gotuzzo E. Practical guidelines for the treatment of cholera. Drugs 1996;51(6):966-73.
97. Tuite A R, Tien J, Eisenberg M, Earn D J, Ma J, Fisman D N. Cholera epidemic in Haiti, 2010: using a transmission model to explain spatial spread of disease and identify optimal control interventions. Annals of Internal Medicine 2011;154(9):593-601.
98. WHO. Case management for cholera. http://www.emro.who.int/Arabic/sudan/media/pdf/Cholera_CaseManagement.pdf.
99. Sack DA, Lyke C, McLaughlin C, Suwanvanichkij V. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO: http://whqlibdoc.who.int/HQ/2001/WHO_CDS_CSR_DRS_2001.8.pdf 2001.
100. World Health Organization. Cholera outbreak: assessing the outbreak response and improving preparedness. http://www.who.int/topics/cholera/publications/cholera_outbreak/en/ 2004.
101. World Health Organization. Weekly epidemiological record. 31 July 2009, 84th year. No. 31, 2009, 84, 309-24. http://www.who.int/wer/2009/wer8431.pdf.
102. World Health Organization. Cholera in Zimbabwe: update 4. http://www.who.int/csr/don/2009_06_09/en/index.html.
103. WHO. Cholera in Mexico - update. http://www.who.int/csr/don/2013_10_28/en/.
104. Wood L, Egger M, Gluud L L, Schulz K F, Juni P, Altman D G, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. British Medical Journal 2008;336(7644):601-5.
105. Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infectious Diseases 2007;7(8):521-30.